ORYZON GENOMICS S.A. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.028 EUR | -0.10% |
|
+3.30% | +7.79% |
| 06/05 | Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 22/04 | Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 127M | - | - | - | - | - | |
| 49.18B | - | |||||
| 42.11B | ||||||
| 40.37B | ||||||
| 28.85B | ||||||
| 26.09B |
- Stock Market
- Equities
- ORY Stock
- Charts Oryzon Genomics S.A.
- Sector Chart